Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Kidney cancer

No advantage of adjuvant sunitinib or sorafenib

Nature Reviews Urology volume 13, pages 240–241 (2016)Cite this article

Subjects

Treatment with adjuvant sunitinib or sorafenib confers no survival benefit on patients with completely resected, nonmetastatic, high-risk clear cell or non-clear cell renal cell carcinoma (RCC), according to the results of a double-blind, placebo-controlled, randomized, phase III trial published in the Lancet. Moreover, considerable treatment discontinuation occurred owing to toxicity.

This study was conducted at 226 centres in the USA and Canada, in total, 1,943 patients were allocated to receive 50 mg sunitinib daily for 4 weeks of each 6-week cycle, 400 mg sorafenib twice daily throughout the cycle, or placebo in a 1:1:1 ratio, treatment duration was 54 weeks.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(16)00559-6 (2016)

  2. Duensing, S. and Hohenfellner, M. Adjuvant therapy for renal-cell carcinoma: settled for now. Lancet http://dx.doi.org/10.1016/S0140-6736(16)00653-X (2016)

Download references

Authors
  1. Louise Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stone, L. No advantage of adjuvant sunitinib or sorafenib. Nat Rev Urol 13, 240–241 (2016). https://doi.org/10.1038/nrurol.2016.63

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.63

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing